DE-117 ophthalmic solution + Timolol ophthalmic solution

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Open Angle Glaucoma or Ocular Hypertension

Conditions

Open Angle Glaucoma or Ocular Hypertension

Trial Timeline

Jul 1, 2016 โ†’ Nov 9, 2017

About DE-117 ophthalmic solution + Timolol ophthalmic solution

DE-117 ophthalmic solution + Timolol ophthalmic solution is a phase 3 stage product being developed by Santen Pharmaceutical for Open Angle Glaucoma or Ocular Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT02822729. Target conditions include Open Angle Glaucoma or Ocular Hypertension.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02822729Phase 3Completed

Competing Products

20 competing products in Open Angle Glaucoma or Ocular Hypertension

See all competitors